Physician profile
Kyle J King
NPI 1982604625
$7,323.55
in general payments reported to CMS, 2019-2025
40 companies · $874 in 2025
The $874 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $851 · 2021: $1,084 · 2022: $1,095 · 2023: $1,102 · 2024: $1,229 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $875.52 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $801.24 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $643.51 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $601.84 | 2019-2025 | |
| Amarin Pharma, INC. | $544.15 | 2019-2023 | |
| Lilly USA, LLC | $412.99 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.72 | 2019-2025 | Jardiance |
| Abbvie INC. | $351.43 | 2021-2025 | |
| Amgen INC. | $250.57 | 2022-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.05 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $162.08 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $161.65 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $153.01 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $149.90 | 2019-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $126.60 | 2022-2025 | Rexulti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.